1 July -
Summary of the Interim Report
Net sales of 0.6 MSEK (0.0 MSEK)
Other income amounted to 0.0 MSEK (0.0 MSEK)
Third quarter of 2023
- R&D costs for the period amounted to 7.4 MSEK (10.9 MSEK)
- Profit after tax amounted to -10.8 MSEK (16.1 MSEK) ∞ Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -7.3 MSEK (-3.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 2.3 MSEK (6.7 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 50.7 MSEK (39.3 MSEK)
The period January-
- Net sales of 7.1 MSEK (3.7 MSEK)
- Other income amounted to 0.3 MSEK (0.4 MSEK)
- R&D costs for the period amounted to 23.0 MSEK (42.7 MSEK)
- Profit after tax amounted to -26.3 MSEK (-50.9 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -18.6 MSEK (-39.1 MSEK)
For more information, visit the
scott.boyer@klaria.com
Tel: +46 8-446 42 99
This is
Klaria (
https://news.cision.com/klaria-pharma-holding-ab/r/klaria-interim-report-q3-2023,c3882377
https://mb.cision.com/Main/12655/3882377/2453070.pdf
https://mb.cision.com/Public/12655/3882377/ab5b34d504540c01.pdf
(c) 2023 Cision. All rights reserved., source